Introduction
============

Obscurin is a giant scaffold protein present in striated muscles initially identified on the basis of its ability to bind titin ([@bib61]; [@bib34]). The structural layout of obscurin is based on in-tandem arrangements of adhesion and signaling domains that include intracellular immunoglobulin and fibronectin III--like domains, an IQ motif, an SH3 (src homology 3) domain, a RhoGEF (double homology domain), and a pleckstrin homology motif. In adult skeletal muscles, the predominant isoform, obscurin A, is characterized by a nonmodular region of 420 aa residues bearing several putative extracellular signaling--regulated kinase phosphorylation sites ([@bib61]). In a second isoform of higher molecular weight, obscurin B, the nonmodular C-terminal sequence is replaced by two serine/threonine kinase--like domains ([@bib55]; [@bib23]). In addition, two other smaller variants consisting only of the kinase domains (tandem myosin light chain kinase and skeletal myosin light chain kinase) have been characterized ([@bib9]). Given the modular architecture consisting of structural and signaling domains, obscurin is involved in several interactions that are important for the organization of contractile proteins in the sarcomere ([@bib12]). Indeed, obscurin participates in the M-band assembly via interactions with titin and myomesin ([@bib24]). Finally, the RhoGEF domain of obscurin mediates direct binding to RANBP-9 and is involved in the activation of small GTPase proteins, such as RhoA and RhoQ/TC10 ([@bib10]; [@bib13]; [@bib22]).

In addition to sarcomeric proteins, obscurin can interact with some isoforms of ankyrin proteins ([@bib5]; [@bib32]; [@bib2]; [@bib8]; [@bib15]). Ankyrins are versatile adaptor proteins that coordinate the assembly of a molecular "bridge" between integral membrane proteins and the spectrin-based cytoskeleton, thereby promoting the assembly of protein complexes at specific regions of the plasma membrane ([@bib6]; [@bib7]; [@bib16]). In vertebrates, three genes (*ank1*, *ank2*, and *ank3*, which encode proteins named ankR, ankB, and ankG, respectively) generate multiple isoforms, expressed in a tissue-specific manner and classified according to their size as giants (480--270 kD), canonical (220--190 kD), and small ankyrins (20 kD; [@bib6]). Ankyrins have a complex molecular structure consisting of a membrane-binding domain that mediates the interaction with the cytoplasmic region of trans-membrane proteins, a spectrin-binding domain (SBD) that connects to the cytoskeleton, and two additional regions, the death domain and the C-terminal regulatory domain ([@bib6]). A low molecular weight isoform encoded by the *ank1* gene, sAnk1.5 (or small ank1), contains an N-terminal trans-membrane sequence that embeds this protein within the sarcoplasmic reticulum (SR) membrane ([@bib62]). The cytoplasmic region of sAnk1.5 contains an amino acid sequence that is able to mediate the interaction with the C-terminal region of obscurin ([@bib5]; [@bib32]; [@bib2]). In striated muscles, sAnk1.5 colocalizes with obscurin. Both proteins are observed predominantly in correspondence of the M band but can be also found at lower levels in close proximity to the Z disk ([@bib27]). Site-directed mutagenesis of the specific amino acid residues in sAnk1.5 that are required for interaction with obscurin impaired the ability of sAnk1.5 to localize to the M band in cultured muscle cells ([@bib5]; [@bib17]). In addition, siRNA-induced knockdown of obscurin altered the organization of SR in C2C12 cells ([@bib33]; [@bib1]). Accordingly, in an obscurin knockout (KO) mouse model, sAnk1.5 was mislocalized to the Z disk, and the overall architecture of the longitudinal SR, but not that of the junctional SR, was altered ([@bib35]). These results agree with a model in which the interaction between obscurin and sAnk1.5 is necessary for tethering the SR to the contractile apparatus ([@bib54]; [@bib58]). Further observations have shown that a 76-aa sequence, bearing two obscurin-binding domains (OBDs), is present in almost all ankyrin isoforms expressed in striated muscles ([@bib5]; [@bib31]). In cardiac myocytes, the 220-kD muscle-specific isoform ankB, encoded by the *ank2* gene, plays a role in the assembly of Na/K ATPase, Na/Ca exchanger, and inositol trisphosphate receptor proteins in specialized microdomains involved in the regulation of intracellular calcium homeostasis at t (transverse) tubules ([@bib44]). Cardiac myocytes express two ankB splice variants containing one or two OBDs that, by interacting with obscurin, target the phosphatase A2 protein to the M-band region of the sarcomere ([@bib15]). In skeletal muscle, six ankG isoforms, encoded by the *ank3* gene, all containing the two OBDs, are also expressed and shown to localize at the subsarcolemma level in alignment with the Z disk ([@bib25]; [@bib31]). Furthermore, [@bib40] reported that the very same 76 aa residues that bind obscurin can also interact with the cytoskeletal proteins plectin and filamin C.

More recently, two muscle-specific ankyrin isoforms, ankB and ankG, have been shown to have a key role in the organization of dystrophin and β-dystroglycan at costameres and at neuromuscular junctions in skeletal muscles fibers ([@bib3], [@bib4]). Dystrophin and β-dystroglycan participate in the assembly of the dystrophin--glycoprotein complex (DGC), containing integral membrane components (sarcospan, α-, β-, γ-, and δ-sarcoglycans, and β-dystroglycan) and peripheral membrane proteins (α-dystroglycan, α1/β1-syntrophins, and dystrophin; [@bib14]; [@bib19]). The DGC represents the structural core of the costameres, which are specialized membrane domains formed at the junction between the sarcolemma and the Z disk of peripheral myofibrils ([@bib46]). Evidence of costamere-like protein assemblies in register with the M bands has been also reported; however, their composition and function remain poorly understood ([@bib45]). The membrane-spanning DGC confers stability to the sarcolemma linking the subcortical cytoskeleton to the ECM, therefore acting as a force-buffering system that prevents structural damage during contraction ([@bib18]; [@bib19]). Indeed, the N-terminal region of dystrophin is able to bind subsarcolemmal γ-actin ([@bib50]) and α-tubulin ([@bib51]). Other components of the DGC are stably connected to intermediate filament--associated proteins: α-dystrobrevin and β-dystroglycan are directly linked to plectin-1 and -1F ([@bib53]; [@bib29]), whereas γ- and δ-sarcoglycans interact with filamin C ([@bib59]). Notably, in the Duchenne muscular dystrophy, mutations in the dystrophin gene affect DGC stability, resulting in sarcolemma fragility and hence muscle degeneration ([@bib30]).

[@bib3] used gene silencing techniques to demonstrate that lack of ankB prevented localization of dystrophin and β-dystroglycan to the sarcolemma, whereas ankG was necessary for their localization at costameres and for maintenance of sarcolemma integrity. In particular, ankB, which is recruited to Z disks by β2-spectrin, is necessary for proper delivery of dystrophin and β-dystroglycan to the sarcolemma through direct binding to dynactin-4, a microtubule-associated protein that is responsible for the assembly of a specific set of subsarcolemmal microtubules ([@bib3]). These authors proposed a hierarchical model, in which the organization of a functional DGC at the costamere level starts with the recruitment of ankB by the cytoskeletal protein β2-spectrin. AnkB in turn, interacts with both dystrophin and dynactin-4 to coordinate the correct delivery of dystrophin and β-dystroglycan through the subsarcolemma microtubule cytoskeleton ([@bib4]).

Given that the organization of costameres depends on multiple interactions and that all muscle-specific ankyrin isoforms contain OBDs, we raised the question whether obscurin may also contribute to the assembly of dystrophin and β-dystroglycan at costameres. Our results indicate that localization of ankB, but not ankG, requires the expression of obscurin. Moreover, deletion of obscurin altered the localization of dystrophin at costameres and the organization of costamere-associated microtubules and was accompanied by sarcolemma fragility after exercise.

Results
=======

Localization of ankB, but not of ankG, is lost in skeletal muscle fibers of obscurin KO mice
--------------------------------------------------------------------------------------------

Confocal microscopy imaging along the longitudinal axis of flexor digitorum brevis (FDB) fibers from adult control mice showed that obscurin and ankB have an identical localization pattern. Major staining of both proteins alternated with that obtained with an antibody against the Z-disk protein α-actinin and was therefore compatible with M-band localization. However, a weaker decoration was also detectable at the Z-disk level ([Fig. 1, A, B, D, E, G, and H](#fig1){ref-type="fig"}). Conversely, the ankG protein was predominantly aligned in correspondence of the Z disk ([Fig. 1, C, F, and I](#fig1){ref-type="fig"}). In cross sections of the tibialis anterior muscle, obscurin, ankB, and ankG were localized at the subsarcolemma level ([Fig. 1, J--L](#fig1){ref-type="fig"}), as also reported in human striated muscles ([@bib11]). However, although the obscurin signal was also evident in the interior part of muscle fibers, ankB and ankG staining yielded a clear signal at the subsarcolemma level. To verify whether obscurin is required for localization of ankB and ankG proteins in mouse skeletal muscle, we used a previously described obscurin KO mouse model ([@bib35]). Immunostaining of skeletal muscle fibers from FDB muscle of control and obscurin KO mice revealed that the typical localization pattern of ankB at the M band was lost in obscurin KO mice skeletal muscle fibers, with most of the ankB immunofluorescence signal yielding an apparently nonorganized distribution (compare [Fig. 2, B and E](#fig2){ref-type="fig"}). It is worth noting that, in skeletal muscle fibers from obscurin KO mice, a minor fraction of ankB staining was also detectable at the Z disk ([Fig. 2 H](#fig2){ref-type="fig"}). On the contrary, the localization pattern of ankG was similar in skeletal muscle fibers from control and obscurin KO mice ([Fig. 2, C, F, and I](#fig2){ref-type="fig"}). Altogether, these data indicate that obscurin is required for localization of ankB, but not of ankG, in skeletal muscle fibers. To test the possibility that obscurin and ankB may associate in skeletal muscle fibers, immunoprecipitation experiments were performed with solubilized proteins from skeletal muscle lysates using an antibody against the C-terminal region of obscurin. As shown in [Fig. 2 J](#fig2){ref-type="fig"}, ankB, but not ankG, was coimmunoprecipitated in skeletal muscle lysates from control mice, in agreement with previous data obtained in cardiac muscle ([@bib15]). Under these experimental conditions, sAnk1.5 was also coimmunoprecipitated with obscurin. In contrast, ankB and sAnk1.5 were not coimmunoprecipitated in skeletal muscle lysates from obscurin KO mice. The interaction between obscurin and ankB and sAnk1.5 was confirmed by GST pull-down experiments ([Fig. 2 K](#fig2){ref-type="fig"}) using skeletal muscle lysates from control mice and a GST fusion protein (A7VI) containing the C-terminal region of obscurin encompassing the ankyrin binding sites ([@bib2]).

![**Localization of obscurin, ankB, and ankG in control skeletal muscle fibers.** (A--I) Immunostaining of FDB fibers from control mice shows colocalization of obscurin (A, D, and G) and ankB (B, E, and H) at the M band. Conversely, ankG (C, F, and I) is predominantly localized in coincidence to the Z disk. α-Actinin is used to mark the Z disks. Bar, 5 µm. (J--L) Analysis of tibialis anterior cross sections shows obscurin (J), ankB (K), and ankG (L) localized at the subsarcolemmal region. Bar, 20 µm.](JCB_201205118_Fig1){#fig1}

![**Localization of ankB is altered in skeletal muscle fibers of obscurin KO mice.** (A--I) Comparison of obscurin (A, D, and G), ankB (B, E, and H), and ankG (C, F, and I) localization between control and KO mice reveals that, in absence of obscurin, ankB localization at the M band is lost, whereas a fuzzy localization (E) or a weak alignment at the Z disk (H) remain. AnkG is unaffected in obscurin KO fibers (F and I). α-Actinin marks Z disks as shown in the merged images reported in the insets. Bar, 10 µm. (J and K) In vivo and in vitro interactions of obscurin with ankB and sAnk1.5. (J) AnkB and sAnk1.5 were coimmunoprecipitated with an antibody against obscurin from skeletal muscle lysates of control mice (third lane) but not from those of obscurin KO mice (sixth lane). No band was detected with an unrelated antibody (second lane). Arrowhead indicates the band corresponding to sAnk1.5. (K) GST pull-down assays. GST fusion protein A7VI, containing the C-terminal region of obscurin (aa 6,215--6,353) was used to pull down ankB and sAnk1.5 from skeletal muscle lysates. First lane shows 10 µl of total muscle lysate; second lane shows proteins pulled down with GST-A7VI; third lane shows proteins pulled down with GST as a control. IB, immunoblot.](JCB_201205118_Fig2){#fig2}

Targeting of ankB to the M band requires the presence of OBDs
-------------------------------------------------------------

Next, we asked whether M-band localization of ankB in mouse skeletal muscle fibers was dependent on the two OBDs in the C terminus of ankB. Plasmids encoding GFP-tagged ankB protein (GFP-ankB) or GFP-ankB mutant proteins lacking two (GFP-ankB-ΔOBD1/2) or either one of the OBDs (GFP-ankB-ΔOBD1 and GFP-ankB-ΔOBD2) were prepared ([Fig. 3 A](#fig3){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201205118/DC1){#supp1}). These plasmids were in vivo electroporated into FDB muscles of control and obscurin KO mice, and confocal microscopy analysis was performed 8 d after electroporation. As expected, the GFP-ankB protein signal in control fibers was distinct from that obtained with an antibody against α-actinin yielding a localization pattern at the M-band region ([Fig. 3, B, D, and F](#fig3){ref-type="fig"}). In contrast, the GFP-ankB protein colocalized with α-actinin at Z disks in obscurin KO animals ([Fig. 3, C, E, and G](#fig3){ref-type="fig"}), with GFP-ankB displaying a significantly wider signal than that observed with the antibody against α-actinin. Conversely, the GFP-ankB-ΔOBD1 mutant showed a diffuse signal around the Z disk, both in skeletal muscle fibers from control and obscurin KO mice ([Fig. 3, H--M](#fig3){ref-type="fig"}). Similar results were observed with GFP-ankB mutants lacking OBD2 (GFP-ankBΔOBD2) or both OBD1 and OBD2 (GFP-ankBΔOBD1/2; Fig. S1, B--M). Reported evidence has shown that association of ankB to costameres in correspondence to Z disks requires the direct interaction of ankB with β2-spectrin ([@bib4]). FDB muscle fibers from control, obscurin KO, and mdx mice were stained with an antibody against β2-spectrin. As previously described ([@bib45]; [@bib3]), β2-spectrin appeared as a gridlike network underneath the sarcolemma with a predominant staining in correspondence to the Z disk and, to a lesser degree, at the M band of control and obscurin KO mice ([Fig. S2, A, B, D, E, G, and H](http://www.jcb.org/cgi/content/full/jcb.201205118/DC1){#supp2}). In contrast, the β2-spectrin localization pattern in FDB muscle fibers from mdx mice revealed a reduced staining at the M band, whereas staining at the Z disk was not affected (Fig. S2, C, F, and I). This finding is in agreement with previously reported localizations of β-spectrin in mdx mice by [@bib60]. We therefore prepared a mutant GFP-tagged ankB protein (GFP-ankB-ΔSBD) lacking aa 966--1,125 that contains the ZU5 domain + 55 aa that corresponds to the minimal SBD in ankB ([@bib43]). In addition, a construct deleted of the SBD and of the two OBDs (GFP-ankB-ΔSBD-ΔOBD1/2) was prepared ([Fig. 4 A](#fig4){ref-type="fig"}). After electroporation of the GFP-ankB-ΔSBD plasmid into FDB muscle, the fluorescence signal was observed at the M band in skeletal muscle fibers from control mice ([Fig. 4, B, D, and F](#fig4){ref-type="fig"}), whereas in fibers from obscurin KO mice, only a residual staining around the Z-disk region was observed ([Fig. 4, C, E, and G](#fig4){ref-type="fig"}). Electroporation of the FDB muscle with the GFP-ankB mutant lacking the SBD and both OBDs yielded only a fuzzy signal over the Z disks in skeletal muscle fibers from control mice and an even more disorganized staining in those from obscurin KO mice ([Fig. 4, H--M](#fig4){ref-type="fig"}). To confirm these observations, we prepared two GFP fusion proteins, one containing only the minimal SBD amino acid sequence (GFP-SBD) and one containing only the two OBD amino acid sequences (GFP-OBD1+2) of ankB ([Fig. S3, A and B](http://www.jcb.org/cgi/content/full/jcb.201205118/DC1){#supp3}). Electroporation of these two constructs into the FDB muscle of control mice indicated that the GFP-SBD fusion protein was localized at the Z disk, whereas the GFP-OBD1+2 fusion protein was localized at the M band, thus reflecting the ability of these two domains to establish specific direct interactions with β2-spectrin and obscurin, respectively (Fig. S3, C--H). Altogether, our results indicate that ankB protein localization at the M band relies on the interaction with obscurin. As a consequence, lack of obscurin as well as the altered binding capacity determined by the absence of one or both OBDs, restricts the ankB localization at the Z-disk level, at which localization may require the SBD to interact with β2-spectrin. Whether the smaller fraction of obscurin localized at the Z disk contributes to localization of ankB to this site remains unclear, but it is certainly less evident than the contribution of β2-spectrin.

![**The two OBDs in ankB are necessary for localization at the M band in skeletal muscle.** (A) Schematic representation of GFP-tagged constructs used for in vivo electroporation of FDB muscles of control and obscurin KO mice (MBD, membrane-binding domain; SBD, spectrin-binding domain; DD, death domain; RD, regulatory domain containing the two OBD sites). (B--G) The construct containing two OBDs (GFP-ankB) localizes at the M band (B, D, and F) in control fibers, whereas in obscurin KO fibers, the staining is observed at the Z disk (C, E, and G). (H--M) The construct lacking OBD1 (GFP-ankB-ΔOBD1) displays a fuzzy localization in coincidence with Z disks both in control (H, J, and L) and obscurin KO fibers (I, K, and M). α-Actinin is used to mark Z disks. Bars, 5 µm.](JCB_201205118_Fig3){#fig3}

![**The SBD is necessary for ankB localization in the alignment to Z disks.** (A) Schematic representation of GFP-tagged ankB mutants lacking either only the amino acid residues (966--1,125), corresponding to the minimal spectrin-binding domain (SBD) or the SBD and both OBDs used for in vivo electroporations of FDB muscles (MBD, membrane-binding domain; ZU5 domain, domain found in ZO-1 and Unc-5-like netrin receptor 5; DD, death domain; RD, regulatory domain containing the two OBD sites). (B--G) The ankB mutant lacking the SBD (GFP-ankB-ΔSBD) localizes at the M band (B, D, and F) in control but not in obscurin KO fibers (C, E, and G) where its localization is diffused. (H--M) The mutant lacking SBD and both OBDs (GFP-ankB-ΔSBD-ΔOBD1/2) shows a diffuse localization both in control (H, J, and L) and obscurin KO muscle fibers (I, K, and M). α-Actinin is used to mark Z disks. Bars, 5 µm.](JCB_201205118_Fig4){#fig4}

Ablation of obscurin alters the localization of dystrophin but not of β-dystroglycan and sarcoglycans at costameres and impairs the correct assembly of the subsarcolemma microtubule cytoskeleton
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AnkB and ankG have recently been shown to be required for the localization of dystrophin and β-dystroglycan at costameres ([@bib3]). We therefore wanted to verify whether the observed mislocalization of ankB in obscurin KO mice could affect dystrophin and/or β-dystroglycan organization. Surprisingly, immunostaining of FDB muscle fibers from control and obscurin KO mice revealed that subsarcolemma localization of dystrophin was markedly reduced in obscurin KO muscle fibers, although a residual dystrophin staining at costameres could still be observed ([Fig. 5, A and D](#fig5){ref-type="fig"}). The dystrophin expression in fibers from skeletal muscles of obscurin KO and control mice stained with the MANDRA1 monoclonal antibody against dystrophin was analyzed using ImageJ software (National Institutes of Health). Image analysis revealed that the dystrophin signal in fibers from obscurin KO muscle was decreased by 62.12 ± 15% compared with that detected in control mice (299.00 ± 119 and 789.25 ± 433 arbitrary units, respectively, *n* = 40; P \< 0.001). In contrast, no difference was observed in the intensity of the staining nor in the localization pattern of β-dystroglycan ([Fig. 5, B and E](#fig5){ref-type="fig"}). Additional immunostaining experiments aimed to verify the localization of α-, β-, γ-, and δ-sarcoglycans ([Fig. S4, A--H](http://www.jcb.org/cgi/content/full/jcb.201205118/DC1){#supp4}), γ-actin (Fig. S4, I and K), and β1D-integrin (Fig. S4, J and L) revealed no alteration in the localization of these proteins at costameres/Z disks in skeletal muscle fibers of obscurin KO mice. Nevertheless, α-tubulin immunostaining of FDB fibers of obscurin KO mice revealed an aberrant distribution of the subsarcolemmal microtubules ([Fig. 5, C and F](#fig5){ref-type="fig"}). These results agree with the data obtained by [@bib3] and with recent findings from a study of dystrophin-deficient mdx mice, in which the costamere-associated microtubule cytoskeleton is disrupted ([@bib51]). The reduced dystrophin localization at the subsarcolemma in skeletal muscles was also confirmed in tibialis anterior cross sections, where the sarcolemma was visualized by Alexa Fluor 488--conjugated WGA staining ([Fig. S5, A--F](http://www.jcb.org/cgi/content/full/jcb.201205118/DC1){#supp5}). No effects were observed, in obscurin KO muscle fibers, on the localization of other membrane proteins, including dihydropyridine receptor on t tubules, caveolin-3 at the sarcolemma, and ryanodine receptor type 1 at the SR, confirming the specificity of the effect determined by the lack of obscurin on dystrophin localization ([Fig. 5, G--L](#fig5){ref-type="fig"}). Interestingly, Western blot analysis on total protein lysates from tibialis anterior, extensor digitorum longus (EDL), and soleus muscles revealed comparable expression levels of ankB and dystrophin in control and obscurin KO mice (Fig. S5 G) as also reported by [@bib3] in skeletal muscle fiber knockdown for ankB. To investigate the discrepancy between the observed reduction in dystrophin levels from the sarcolemma of obscurin KO muscles and the unaltered dystrophin protein levels, we analyzed soluble protein fractions from control and obscurin KO muscles on sucrose gradients. In control muscle, dystrophin and other components of the DGC formed a tightly bound complex enriched in fractions 3--5, in which 84.61 ± 9.56% of the dystrophin protein was present ([Fig. 6, A--D](#fig6){ref-type="fig"}). In contrast, in obscurin KO muscles, only 38.00 ± 5.65% of total dystrophin was associated with other core components of the DGC in fractions 3--5, whereas the remaining dystrophin was detected in fractions 7--13 ([Fig. 6 A](#fig6){ref-type="fig"}). Intriguingly, β-dystroglycan, α-sarcoglycan, and γ-sarcoglycan were still found only in fractions 3--5 of the gradients of obscurin KO muscles ([Fig. 6, C--H](#fig6){ref-type="fig"}). Additionally, the redistribution of dystrophin in obscurin KO mice was not associated with other membrane components, such as caveolin-1 and -3 and β1D-integrin ([Fig. 6, I--N](#fig6){ref-type="fig"}), when compared with control muscles. In summary, muscles from obscurin KO mice display a characteristic reduction of dystrophin from the sarcolemma-bound DGC in immunofluorescence images, without an apparent effect on other DGC components. Biochemical analysis of DGC components further revealed that dystrophin was redistributed in obscurin KO muscles from the buoyant high molecular weight DGC fractions to lower molecular weight complexes that may represent non--membrane-associated proteins.

![**Localization of dystrophin at costameres and the organization of the microtubule cytoskeleton are impaired in skeletal muscle fibers of obscurin KO mice.** (A and D) Immunostaining of whole FDB fibers reveals that dystrophin localization at costameres in obscurin KO muscle fibers (D) is markedly reduced compared with control (A). (B and E) Localization of β-dystroglycan (β-DG) appears unchanged. (C and F) The assembly of the subsarcolemma microtubule cytoskeleton is impaired in obscurin KO mice. (G--L) The lack of obscurin does not alter the localization of membrane-bound proteins as revealed by immunostaining for the dihydropyridine receptor (DHPR; G and J), RyR-1 (H and K), and caveolin-3 (I and L). α-Actinin is used to mark Z disks as shown in the merged images reported in the insets. Bars, 10 µm.](JCB_201205118_Fig5){#fig5}

![**Association of dystrophin with the DGC in obscurin KO muscles is reduced.** Analysis of tibialis anterior muscle lysates from control (CNTR) and obscurin KO animals using sucrose gradient fractionation indicated changes to dystrophin distribution in obscurin KO muscles. (A--H) In control muscles (A and B), dystrophin is enriched in fractions 3--5 with other DGC core components like β-dystroglycan (C and D), α-sarcoglycan (E and F), and γ-sarcoglycan (G and H). Obscurin KO muscles, however, display a wider dystrophin distribution pattern (extending into fractions 7--13; A \[bottom\] and B), indicating a weaker association of dystrophin with the DGC. (I--N) Other DGC components as well as caveolin-1 (I and J), caveolin-3 (K and L), and β1D-integrin (M and N) are unchanged in obscurin KO muscle compared with controls. Graphs represent the distribution of the DGC core components present in each fraction and are reported as the percentage of the total protein. Values refer to the blots shown in the figure.](JCB_201205118_Fig6){#fig6}

Obscurin KO mice show reduced exercise tolerance, loss of muscle strength, and sarcolemmal fragility
----------------------------------------------------------------------------------------------------

Previous work demonstrated that EDL muscle contractile performance studied in vitro is not altered in obscurin KO mice ([@bib35]). However, given the importance of dystrophin localization at costameres for maintenance of sarcolemma integrity, we decided to evaluate whether the altered localization of dystrophin could affect the membrane stability of obscurin KO skeletal muscle fibers. To this end, 5-mo-old control and obscurin KO mice were trained to run uphill on a treadmill as detailed in Materials and methods. Surprisingly, the running performance of obscurin KO mice was lower than that of age-matched controls, as the distance covered at exhaustion by obscurin KO mice was lower in the first session and decreased progressively in subsequent sessions ([Fig. 7 A](#fig7){ref-type="fig"}). We reasoned that the different performance of obscurin KO mice expressed in the nonvoluntary running exercise could be explained as loss of muscle strength compared with control mice. On this basis, we performed a forelimbs grip test to evaluate muscle strength at the end of the last session. Indeed, our measurements revealed a 40% reduction in forelimb muscles of obscurin KO mice (49.7 ± 6.7 mN/g in control mice and 28.6 ± 10.5 mN/g in obscurin KO mice; P \< 0.001). We extended the comparison to the performance in downhill running on a treadmill, an exercise that is less energetically demanding but has a greater component of eccentric contractions compared with uphill running. The results confirmed that the distance covered at exhaustion in three subsequent sessions was dramatically decreased in obscurin KO mice ([Fig. 7 B](#fig7){ref-type="fig"}). Finally, to evaluate whether sarcolemma damage could be involved in such a decline of muscle performance, Evans blue dye (EBD) was intraperitoneally injected just before the last running session, and membrane integrity was subsequently evaluated by microscope visualization of EBD uptake in muscle fibers. Analysis of tibialis anterior ([Fig. 8, A and C](#fig8){ref-type="fig"}) and diaphragm ([Fig. 8, B and D](#fig8){ref-type="fig"}) muscles showed a higher number of EBD-positive fibers in obscurin KO muscles (25 ± 0.7% and 35 ± 1.8%) compared with controls (1 ± 0.1% and 5 ± 0.4%); P \< 0.05. Noteworthy, the sarcolemma damage observed after exercise in obscurin KO mice, at least as measured by EBD uptake, is comparable to what was observed in sedentary mdx mice by us and other laboratories ([@bib47]; [@bib41]; [@bib57]). Altogether, these data indicate that the lack of obscurin determines a pronounced muscle weakness likely explained by sarcolemma fragility when obscurin KO muscle fibers are forced to undergo a prolonged mechanical stress.

![**Behavioral assessment of muscle function.** (A) Impaired exercise tolerance in treadmill uphill running: 5-mo-old (*n* = 8) control and obscurin KO mice were treadmill exercised twice a day for 3 d (see Materials and methods for details). The distance traveled by obscurin KO mice is lower and shows a progressive decline in subsequent sessions compared with age-matched control animals. (B) The decline of exercise tolerance measured as distance traveled in subsequent sessions is even more pronounced in downhill running: 5-mo-old control (*n* = 8) and obscurin KO mice (*n* = 8) were treadmill exercised twice a day, but exercise was interrupted at the third session to avoid useless stress to animals. Results are presented as means and SDs. Bars representing SD for mean values corresponding to rounds 1--3 of control and rounds 1 and 2 of obscurin KO mice are not visible because of graph scale. CNTR, control.](JCB_201205118_Fig7){#fig7}

![**Lack of obscurin results in sarcolemma fragility after exercise.** (A--D) Evans blue dye (EBD) was injected intraperitoneally 12 h before the last running session. Analysis of EBD uptake in tibialis anterior (A and C) and diaphragm (B and D) reveals that the obscurin KO condition results in sarcolemma fragility. A higher number of EBD-positive fibers was found in exercised obscurin KO muscles when compared with controls. Bar, 50 µm.](JCB_201205118_Fig8){#fig8}

Discussion
==========

Dystrophin and members of the DGC are key elements in the organization of costameres at Z disks, where they connect the extracellular matrix, the sarcolemma, and the subsarcolemmal cytoskeleton to avoid sarcolemmal damage caused by physical stress associated with muscle contraction ([@bib20]; [@bib19]). Recent results have shown that the assembly of dystrophin and β-dystroglycan at costameres requires expression of the muscle-specific ankyrin isoforms ankB and ankG ([@bib3]). Independent lines of research, over the last years, have also shown that muscle-specific ankyrins, including sAnk1.5 but also ankB and ankG, contain characteristic binding sites for the myofibrillar protein obscurin ([@bib5]; [@bib31]; [@bib15]). Accordingly, we investigated whether obscurin might participate in the subsarcolemma localization of ankB and ankG and, hence, of dystrophin and β-dystroglycan at costameres. Immunostaining experiments indicated that obscurin, ankB, and ankG were localized at the subsarcolemmal level. In particular, ankB and obscurin were predominantly found at the M band and to a much lesser extent at the Z disk, whereas the ankG signal was mainly observed at the Z disk. In skeletal muscle fibers from obscurin KO mice, ankB was no longer localized at the M band but presented a disorganized distribution with a partial alignment observed in correspondence with the Z disk. The ankG localization pattern was not altered in obscurin KO fibers. These results are consistent with a role of obscurin in the localization of ankB at the M band. The localization of ankG at the Z disk could be mediated by interactions of ankG with the intermediate filament--associated proteins plectin-1 and filamin C ([@bib40]). We found that ankB and obscurin can be coimmunoprecipitated from skeletal muscle protein lysates and that both OBDs are required for localization of ankB to the M band. Previous work indicated that β2-spectrin participates in the localization of ankB to the M band in cardiomyocytes ([@bib43]), whereas in skeletal muscle fibers, β2-spectrin appears to contribute to ankB localization at Z disks ([@bib4]). We found that the GFP-ankB fusion protein was predominantly localized at the M-band region in control mice but was redistributed near the Z disk in obscurin KO mice. Therefore, it is conceivable that in the absence of obscurin, which would represent the major M-band localization determinant for ankB, β2-spectrin could represent the only site of localization for ankB at the Z disk in skeletal muscle. Altogether, these results suggest the existence of two separate systems cooperating in the localization of ankB in skeletal muscle fibers, with obscurin being responsible for localization at the M band, whereas β2-spectrin may link ankB at the Z disk. However, based on available data, it cannot be excluded that the small amount of obscurin present at the Z disk may also contribute to localization of ankB at this site.

Knockdown of ankB or β2-spectrin has been reported to result in the complete absence of dystrophin and β-dystroglycan at costameres in skeletal muscle fibers ([@bib4]). This differs from our findings in obscurin KO mice, in which only the localization of dystrophin at costameres was reduced, but not abolished, whereas costameric localization of β-dystroglycan and sarcoglycans was not altered. The residual localization of dystrophin at costameres observed in obscurin KO mice could be explained by the residual amounts of ankB observed in obscurin KO muscle fibers. The presence of ankG at costameres in obscurin KO mice may further explain the preserved localization of β-dystroglycan and sarcoglycans. It should be noted that, both in this study with obscurin KO mice and in previous studies with ankB and β2-spectrin knockdown mice ([@bib3], [@bib4]), the dystrophin signal was either reduced or absent when analyzed by immunostaining, whereas when measured by Western blotting, the dystrophin protein levels were similar to those of control mice. We think that this apparent discrepancy could be resolved considering that dystrophin, if not retained to costameres by ankB, may diffuse either across the sarcolemma and/or remain in internal cellular compartments, thus becoming virtually undetectable by confocal microscopy. Indeed, reduced localization of dystrophin at costameres was also supported by sucrose gradient fractionation experiments that indicated a reduced association of dystrophin with other core members of the DGC in obscurin KO muscles.

In addition, the organization of subsarcolemma microtubules in obscurin KO muscle fibers was severely altered, similarly to what observed after knockdown of β2-spectrin or of ankB and in muscle fibers of mdx mice ([@bib51]; [@bib4]). In a recent study, depletion of obscurin in developing zebrafish embryos has been shown to alter the organization of skeletal muscle, including the pattern of dystrophin and α-dystroglycan ([@bib52]). In the obscurin KO mouse, the reduced localization of dystrophin at costameres is observed in the presence of a preserved organization of other DGC components. Nevertheless, the reduced running endurance capacity and the severe sarcolemmal damage observed in muscle fibers of obscurin KO mice after exercise clearly indicate that the contribution of obscurin to the correct localization of dystrophin at costameres, likely mediated by its interaction with ankB, is required to prevent sarcolemma fragility, even if other components of the DGC are unaffected. However, the reduced exercise tolerance of obscurin KO mice that can be observed already in the first round of uphill running suggests that additional mechanisms, including the altered organization of the SR in obscurin KO mice ([@bib35]; [@bib1]), may contribute to the decreased performance of these mice.

How obscurin deletion and the resulting ankB mislocalization affect the costameric localization of dystrophin at the level of the Z disk is not obvious, given that the main localization of obscurin and ankB is at the level of the M band. It has been demonstrated that ankB can interact directly with dystrophin and, through dynactin-4, with microtubules ([@bib3]). In addition, dystrophin can also directly bind to microtubules ([@bib51]). It is therefore possible to hypothesize that ankB at the M band may contribute to the assembly of subsarcolemmal microtubules that normally extend along the sarcomere to the region of the Z disk where they connect to dystrophin and other costameric proteins (see the proposed model in [Fig. 9](#fig9){ref-type="fig"}). It cannot be excluded that the minor amount of ankB localized at the Z disk can also directly interact with dystrophin. Actually, it is interesting to point out that the effects of β2-spectrin knockdown on ankB and dystrophin localization ([@bib4]) are closely related to those observed here in obscurin KO muscle fibers. It can then be inferred that obscurin and β2-spectrin are both required for the correct localization of ankB, the organization of the subsarcolemmal cytoskeleton, and for dystrophin localization at costameres. As a consequence, absence of either one of these proteins would result in a significant alteration of this system. Obscurin-mediated localization of ankB at the M band recalls early evidence of costamere-like assemblies in register with the M bands that have long been hypothesized ([@bib45]; [@bib49]; [@bib19]). The newly discovered role of the obscurin and ankB interaction at subsarcolemma appears to be supportive of this hypothesis. It is worth noting that the muscle phenotype of obscurin KO mice that lack dystrophin but contain a conserved presence of the dystroglycan complex is clearly different than mdx mice, in which both the dystrophin and dystroglycan complex are absent. Compared with mdx mice, muscles from obscurin KO mice do not undergo a continuous process of degeneration--regeneration, which in mdx older than 4 wk presents many centronucleated fibers, degenerated fibers, fibrosis, and parvicellular infiltration. Such structural alterations accompany the decline of isometric tension developed by diaphragm and limb skeletal muscles ([@bib38],[@bib39]; [@bib21]). In obscurin KO mice, a significant presence of centronucleated fibers was only detected around 1 yr of age ([@bib35]). However, in both mdx and obscurin KO muscle, the sensitivity to stress and, in particular, to eccentric exercise is very pronounced, definitely much more pronounced than in control animals. From this evidence, it would appear as if the presence of the dystroglycan complex is a guarantee that avoids damage in the condition of ordinary activity but is not sufficient when high and repetitive mechanical stresses are applied. Certainly, additional work will be required to better define these specific aspects.

![**Proposed model for the obscurin, ankB, and microtubule network interactions mediating dystrophin localization at the subsarcolemma in skeletal muscles.** In this model, only known or proposed interactions in skeletal muscle are reported. For other interactions occurring in other cell types, please see reviews by [@bib6], [@bib7], and [@bib16]. In skeletal muscle fibers, ankB is predominantly localized at the M band and, to a lesser extent, at the Z disk. AnkB localization at the M band relies on the interaction with obscurin on the sarcomere, whereas localization at the Z disk depends on the interaction with β2-spectrin associated to the actin microfilaments ([@bib4]) and probably with the smaller amount of obscurin at the Z disk. At the M band, a microtubule lattice is organized by dynactin-4, ankB, and obscurin. In parallel, at the Z disk, a complex made by microtubules, dynactin-4, ankB, β2-spectrin, and dystrophin is formed, in which ankB can directly interact with β2-spectrin, dynactin-4, and dystrophin. In the absence of obscurin, this M-band complex is disrupted, causing the subsarcolemmal microtubule lattice to collapse, thus affecting and reducing the dystrophin localization at Z disks. Nevertheless, the small amount of ankB observed in obscurin KO muscle fibers, through the interaction with β2-spectrin at the Z disks, can still support a residual organization of dystrophin at costameres, in addition to direct interactions between dystrophin and the actin microfilaments network and/or other components of the DGC ([@bib12]; [@bib19]). Localization of ankG at costameres may occur via its interactions with β-dystroglycan, plectin, and filamin C in an obscurin-independent manner ([@bib40]).](JCB_201205118_Fig9){#fig9}

In conclusion, the results presented in this work appear to further advance our understanding of the physiological roles of obscurin in the organization of striated muscle cells. The ability to establish multiple interactions with sarcomeric proteins, including titin, myomesin, and myosin-binding protein C, suggests a role of obscurin in the organization of the M band in sarcomeres ([@bib34]; [@bib26]; [@bib48]). Additional evidence has also shown that obscurin, by interacting with the muscle-specific ankyrin isoform sAnk1.5, is important for the correct alignment of the SR along myofibrils ([@bib5]; [@bib32]; [@bib35]) and for sAnk1.5 protein stability ([@bib36]). The data reported here add a new twist to obscurin functions caused by interaction with proteins of the extrasarcomeric cytoskeleton. In fact, our data indicate that obscurin localized at the subsarcolemma contributes to the organization of the membrane-associated microtubule cytoskeleton and to dystrophin localization at costameres, through its interaction with ankB. Accordingly, obscurin appears to represent a multifunctional anchoring protein that, on one hand, establishes interactions with sarcomeric proteins and, on the other hand, enables complex formation with extrasarcomeric proteins, such as the muscle-specific ankyrin isoforms, that help to connect the sarcomeres with the SR and with the subsarcolemmal cytoskeleton.

Materials and methods
=====================

Mice
----

The development of obscurin global KO mice was described previously ([@bib35]). In brief, the obscurin-coding exon 1 was replaced with a lacZ/GFP-H2B/Neomycin (Neo) cassette, whereby *lacZ* and *Neo* genes are flanked by LoxP and FLP recognition target sites, respectively. Mice used in this study were genotyped by duplex PCR on genomic DNA purified from tail tissue with the genotyping kit (Gentra Puregene; QIAGEN), according to manufacturer's instructions, using the following primers: obscurin forward, 5′-TAAGATTCTTTTCTGCAAGCAGTC-3′; obscurin reverse, 5′-AGTGTGTTTTGAGGAAGGAGAGAG-3′; and Neo FLP recognition target forward, 5′-AATGGGCTGACCGCTTCCTCGT-3′.

Immunostaining and confocal microscopy
--------------------------------------

Fibers obtained from FDB of 6--8-mo-old mice were fixed in 1% PFA--0.5% Triton X-100 for 1 h at room temperature. The bundles of fibers were further permeabilized with 0.5% Triton X-100 in Hepes for 3 min and blocked with 10% goat serum in BSA (fraction V; Sigma-Aldrich) for 1 h. 8-µm cross sections were obtained from tibialis anterior and diaphragm using a cryostat (CM1850; Leica) and mounted on Superfrost Plus slides (Thermo Fisher Scientific). Before immunostaining, sections were blocked in 5% goat serum in 0.2% BSA for 1 h. In all immunostaining experiments, primary antibodies were prepared in 1 or 0.2% BSA and incubated overnight at 4°C. After three washes of 10 min each, samples were incubated for 1 h at room temperature with the secondary antibodies. After final washing (three times at 10 min each), samples were mounted on glass slides and covered with coverslips. Samples were imaged using a confocal microscope (LSM510 META; Carl Zeiss) with a Plan-Apochromat 63× oil immersion, 1.4 NA objective. Fluorescent secondary antibodies Cy2-conjugated anti--mouse and Cy3-conjugated anti--rabbit were obtained from Jackson ImmunoResearch Laboratories, Inc. Images were acquired at 23°C using the antifade reagent (ProLong Gold; Invitrogen) as imaging medium with the LSM acquisition software (Carl Zeiss). Image analysis was performed using the ImageJ software. Several regions were drawn in muscle fibers after dystrophin staining, and the dystrophin signal was calculated as the mean intensity within the region, after subtraction of the mean background intensity of a nearby area. In all cases, acquisition conditions within an experiment were identical. Arbitrary units are reported as means ± SD and analyzed by a two-tailed Student's *t* test.

Construct preparation and in vivo electroporation
-------------------------------------------------

GFP constructs were prepared from the pEGFP-N1 plasmid bearing the human ankB sequence containing only the OBD2 site. The full-length ankB sequence was obtained by inserting a fragment containing both the OBD1/2 sites cloned from a human cDNA. The full-length ankB was then transferred into the pEGFP-C2 vector (Takara Bio Inc.). All GFP-tagged constructs used in this study were prepared using pEGFP-C2-ankB as a template. GFP-ankB-ΔOBD1, -ΔOBD2, and -ΔOBD1/2 deletion mutants were obtained by removing one or both OBD sites by PCR. GFP-tagged ΔSBD constructs were obtained by removing the ZU5 domain (ZO-1 and Unc-5-like netrin receptor 5) + 55 aa corresponding to the minimal spectrin-binding region (966--1,125 aa) of ankB as described in [@bib43]. The SBD (943--1,192 aa) and OBD1+2 (1,756--1,871 aa) sequences used for the GFP-SBD and GFP-OBD1+2 constructs, respectively, were cloned from ankB by PCR. All the constructs used in the study were verified by DNA sequencing. In vivo electroporation experiments were performed on FDB muscles injected with 2 mg/ml bovine hyaluronidase (Sigma-Aldrich) 45 min before electroporation ([@bib37]). Control and obscurin KO mice were anesthetized with 1.25% Avertin (Roche) solution, and 10 µg plasmid constructs in 20 µl PBS was injected into the muscle using a microsyringe (Exmire; Ito Corporation). Immediately after injection, muscles were placed between paddle electrodes, and a 20-ms pulse train (120 V, 20-ms length, and 1-s intervals) was delivered using the pulse generator (Electro Square Porator ECM 830; BTX-Genetronics, Inc.). Mice were sacrificed 8 d after electroporation.

Antibodies
----------

Polyclonal rabbit antibodies raised against different epitopes of obscurin were a gift of M. Gautel (King's College London, London, England, UK). The antibody against obscurin was obtained by immunizing rabbits with the A7VI GST fusion protein and has been previously described ([@bib5]; [@bib27]). A polyclonal antibody against ankB was provided by V. Bennett (Duke University, Durham, NC), a polyclonal antibody specific for ankG was provided by K. Kordeli (Centre National de la Recherche Scientifique--Université Jussieu, Paris, France), polyclonal antibody against α-sarcoglycan was obtained from R. Betto (University of Padua, Padua, Italy), and a polyclonal antibody against β1D-integrin was provided by G. Tarone (University of Turin, Turin, Italy). The polyclonal antidystrophin (RB-9024) was purchased from Thermo Fisher Scientific, the monoclonal antidystrophin (clone MANDRA1), the polyclonal antibodies against β-, γ-, and δ-sarcoglycans, the monoclonal anti--α-tubulin (clone B-5-1-2), and the monoclonal antibody anti--α-actinin (clone 5C5) were all purchased from Sigma-Aldrich, the monoclonal anti--β-dystroglycan (product code: NCL-b-DG) was purchased from Novocastra, the polyclonal antibody anti--γ-actin and the AB993 polyclonal antibody anti--β2-spectrin were purchased from EMD Millipore, the monoclonal anti--dihydropyridine receptor was purchased from Thermo Fisher Scientific, the monoclonal anti--caveolin-3 was purchased from BD, a rabbit polyclonal anti--RyR1 (ryanodine receptor type1) was obtained by injecting a GST fusion protein encoding the divergent region 3 of RyR1 as previously described ([@bib28]), and conjugated WGA Alexa Fluor 488 was obtained from Molecular Probes. Antibodies used in sucrose gradient experiments are as follows: Caveolin-1 was obtained from Cell Signaling Technology. Caveolin-3 was obtained from BD. The polyclonal dystrophin antibody (H-300) was purchased from Santa Cruz Biotechnology, Inc. Vector Laboratories provided monoclonal antibodies to α- and γ-sarcoglycans (VP-A105 and VP-G803, respectively). The monoclonal antibody to β-dystroglycan, MANDAG2, developed by G.E. Morris (Institute of Science and Technology in Medicine, Keele University, Staffordshire, England, UK), was obtained from the Developmental Studies Hybridoma Bank. Polyclonal β1D-integrin was produced in the laboratory of B. Ross (University of California, San Diego School of Medicine, La Jolla, CA).

Treadmill exercise, forelimbs grip strength test, and EBD uptake experiments
----------------------------------------------------------------------------

Control and obscurin KO 5-mo-old mice (*n* = 8) were treadmill exercised with a rolling belt instrument (LE 8710M; Panlab) twice a day for 3 d (30 min, 10° uphill angle, and 30 cm/s) for the uphill running according to the protocol proposed by [@bib4], whereas three rounds (45 min, 15° downhill angle, and 20 cm/s) were performed for downhill exercise. The day before final exercises of uphill and downhill, EBD was injected intraperitoneally (1 mg/0.1 ml per 10 g of body weight). After the last running session of uphill running, a forelimbs grip test was performed to measure the maximum strength of forelimbs of all control and obscurin KO mice. In brief, the mice were held by the tail and lowered on a grid connected to a force sensor, allowing only the front paws to grip the grid. The mice were then pulled back horizontally until they released the grid, and six serial strength measurements were recorded. The six strength data were averaged and normalized to body weight and expressed in normals per gram. Tibialis anterior and diaphragm muscles were removed from exercised mice and snap frozen using optimum cutting temperature (Tissue-Tek; Sakura) in cooled isopentane chilled to −165°C in liquid nitrogen. Muscles were cross sectioned (20 µm) throughout the length of the muscles to evaluate the extent of EBD uptake. Positive fibers were imaged with a 20× objective.

Sucrose gradients, SDS-PAGE, and immunoblotting
-----------------------------------------------

Analysis of DGC protein components on sucrose gradients of tibialis anterior muscles obtained from control and obscurin KO mice was performed as previously described ([@bib14]). Muscles were homogenized in ice-cold immunoprecipitation lysis buffer (Thermo Fisher Scientific) supplemented with protease and phosphatase inhibitors (Roche). Soluble proteins were separated from insoluble proteins via centrifugation at 14,000 *g* for 10 min at 4°C. 600 µg of soluble proteins was loaded onto a 5--20% linear sucrose gradient (Gradient immunoprecipitation station; Biocomp Instruments) and placed in an ultracentrifuge (Optima L-90K; Beckman Coulter) at 350,000 *g* overnight at 4°C. The next day, the gradients were fractionated into 13 fractions, and 20--40 µl of each fraction was resolved on 4--20% SDS-PAGE gradient gels and subsequently transferred onto nitrocellulose overnight for immunoblot analysis. For total protein immunoblotting experiments, tissues were homogenized in lysis buffer containing 4 M urea, 3.8% SDS, 20% glycerol, and 75 mM Tris-HCL, pH 6.8, using a homogenizer (ULTRA TURRAX T 10; IKA) three times for 10 s. Lysates were incubated for 1 h on ice and then centrifuged at 10,000 *g* for 5 min at 4°C in a microcentrifuge (Eppendorf), and the supernatant was conserved at −80°C until use. Total muscle proteins were separated by SDS-PAGE using a 5% gel overnight at 4°C (30 V) and then transferred onto polyvinylidene fluoride (PVDF) membrane overnight at 4°C (80 mA). Membranes were blocked with 5% milk in TBS-T (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20) for 1 h at room temperature. Membranes were incubated with primary antibodies diluted in 5% milk in TBS-T for 1 h at room temperature. After three washes with TBS-T of 10 min each, membranes were incubated for 1 h at room temperature with HRP-conjugated secondary antibodies. After further washing with TBS-T (three times for 10 min each), chemiluminescence was detected using the Western blotting reagents (ECL Prime; GE Healthcare). HRP-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc.

Images from different experiments were captured on film and quantified in arbitrary units using ImageJ software. Values are reported as means ± SD and analyzed by two-tailed Student's *t* test.

Coimmunoprecipitation
---------------------

Solubilized proteins from mouse skeletal muscle were prepared as previously described ([@bib44]). In brief, skeletal muscles were dissected, flash frozen in liquid nitrogen, and ground into a fine powder, which was resuspended in 50 mM Tris HCl, pH 7.4, 10 mM NaCl, 0.32 M sucrose, 5 mM Na EDTA, 2.5 mM Na EGTA, 1 mM EDTA, pH 8.0, and protease inhibitors. The homogenate was centrifuged at 1,000 *g* to remove nuclei, and Triton X-100 and deoxycholate were added to the final concentrations of 1.5% Triton X-100 and 0.75% deoxycholate, respectively. The lysate was pelleted at 100,000 *g* for 1 h at 4°C, and the supernatant was recleared at 100,000 *g* for 1 h to remove residual large membranes or vesicles. The resulting supernatant was used for immunoprecipitation. Solubilized proteins were diluted at the concentration of 1 µg/µl in 10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF, and 1 mM Na~3~VO~4~ and precleaned with protein A--Sepharose beads (GE Healthcare) for 1 h at 4°C. 500 µg of precleared solubilized proteins were incubated overnight at 4°C with the antibody against obscurin ([@bib27]) and with an unrelated antibody as a negative control. Afterward, the complexes were incubated with 60 µl protein A--Sepharose beads (50% slurry) for 4 h. Beads were washed four times with dilution buffer to remove nonspecifically bound proteins. The immune complexes were treated with sample buffer and analyzed on 4--15% stain-free precast gels (Criterion-TGX; Bio-Rad Laboratories) transferred on PVDF (EMD Millipore) membranes for immunoblot analysis.

GST pull-down assay
-------------------

100 mg proteins from mouse skeletal muscle was solubilized in 1 ml TBS containing 1% Triton X-100 and protease inhibitors as previously described by [@bib42] and resuspended at the concentration of 1 µg/µl. Pull-down assays were performed with 500 µg protein lysates from skeletal muscle and 15 µg of the A7VI-GST fusion protein (50 µl of beads with 50% slurry) containing the C-terminal region of obscurin (aa 6,215--6,353) encompassing the ankyrin binding sites ([@bib2]) and GST as negative control in pull-down buffer (20 mM Tris, pH 8, 200 mM NaCl, 1% Triton X-100, 1 mM PMSF, 1 mM Na~3~VO~4~, 1 mM EDTA, pH 8.0, and protease inhibitors). After 2 h at 4°C, the complexes were washed four times with pull-down buffer ([@bib56]; [@bib2]). Bound proteins were eluted and separated by SDS-PAGE using 4--15% stain-free precast gels (Criterion-TGX) transferred onto PVDF membranes overnight for immunoblot analysis.

Statistics
----------

Statistical analysis was performed using the Student's *t* test. Results are presented as means ± SD, and p-values are shown.

Online supplemental material
----------------------------

Fig. S1 shows the localization of GFP-ankB-ΔOBD2 and GFP-ankB-ΔOBD1/2 in vivo FDB muscles of control and obscurin KO mice. Fig. S2 shows localization of β2-spectrin in control, obscurin KO, and mdx muscle fibers. Fig. S3 shows localization of GFP-SBD and GFP-OBD1+2 in FDB muscle fibers of control mice. Fig. S4 shows immunofluorescence analysis for α-, β-, γ-, and δ-sarcoglycans, β1D-integrin, and γ-actin in control and obscurin KO muscle fibers. Fig. S5 shows immunostaining of tibialis anterior cross sections with WGA and dystrophin (MANDRA1) antibodies and Western blot analysis of protein lysates from tibialis anterior, EDL, and soleus of control and obscurin KO mice. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201205118/DC1>. Additional data are available in the JCB DataViewer at <http://dx.doi.org/10.1083/jcb.201205118.dv>.
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